SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

CBL Control Bionics Limited

Healthcare · Medical Devices · website
$0.06
52wk 0.03 – 0.10
Overall
44.5
Value
79.0
Growth
12.4
Health
74.9
Quality
0.0
Momentum
45.2
Dividend
—
Price
About Control Bionics Limited

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; and switch systems comprising proximity, press, and finger switches. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.

Price analytics

Returns

1 day -1.6%
1 week 7.0%
1 month -1.6%
3 months -18.7%
6 months 1.7%
1 year 84.8%
3 years -3.4%

Risk

Volatility (1y ann.) 106.9%
Beta vs ASX 200 0.18
Sharpe (1y) 1.00
VaR 95% (1-day) -6.7%
Max drawdown (1y) -39.8%
Off 1-year high -34.4%

Technicals

RSI(14) 50
vs 50DMA -0.7%
vs 200DMA -4.3%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 79.0
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
55
Price / Sales
33
Growth 12.4
Revenue growth (1y)
12
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 74.9
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
44
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 45.2
6-month return vs ASX 200
52
Price vs 200-day average
36
Price vs 50-day average
47
Position in 52-week range
46

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$33.13M
P/E (trailing)
—
P/E (forward)
-3.05
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.10
EV / EBITDA
-5.27
Price / Book
4.07
ROE
-122.9%
Operating margin
-181.5%
Net margin
-152.4%
Total cash
$2.15M
Total debt
$618,925
Current ratio
1.54
Debt / Equity
0.10
Free cash flow
$-3.10M
Avg volume
542,734
Latest annual results (FY ending 30 Jun 2025)
  • Revenue—
  • Gross profit—
  • Operating income—
  • Net income—
  • Diluted EPS-0.02
  • Free cash flow—
  • Net debt—
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4